MYCi975

CAS : 2289691-01-4

Ref. 3D-PRD69101

Informations sur le produit

• Nom: MYCi975

Description

MYCi975 is a drug candidate in the development of cancer-targeted therapies. MYCi975 binds to and inhibits the activity of the protein c-Myc, which plays a critical role in tumor formation and progression. This drug has been shown in vivo to inhibit tumor growth through apoptosis induction and cell cycle arrest. MYCi975 has also been shown to have anti-angiogenic effects and induce an immune response against tumors by stimulating T-cell production and proliferation. MYCi975 has shown promising results in vitro for pancreatic cancer, glioma, breast cancer, and other cancers that express the HER2 oncoprotein.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 561.3 g/mol
• Formule: C₂₅H₁₆Cl₂F₆N₂O₂
• Degré de pureté: Min. 95%